Get the Stockscreener App
178.96
1.47%
2.595
After Hours:
179.21
0.25
+0.14%
Biogen Inc stock is traded at $178.96, with a volume of 1.55M.
It is up +1.47% in the last 24 hours and down -1.43% over the past month.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
See More
Previous Close:
$176.37
Open:
$177.71
24h Volume:
1.55M
Relative Volume:
1.19
Market Cap:
$26.26B
Revenue:
$9.53B
Net Income/Loss:
$1.29B
P/E Ratio:
20.32
EPS:
8.8057
Net Cash Flow:
$1.97B
1W Performance:
+1.91%
1M Performance:
-1.43%
6M Performance:
+23.16%
1Y Performance:
+50.06%
1-Day Range:
$177.45
$181.77
1-Week Range:
$171.22
$181.77
52-Week Range:
$114.66
$202.41
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
178.96 | 25.38B | 9.53B | 1.29B | 1.97B | 8.8057 |
LLY
Lilly Eli Co
|
922.50 | 839.28B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
240.10 | 574.36B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
210.26 | 367.80B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
204.38 | 316.42B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
119.96 | 299.89B | 64.93B | 18.26B | 12.36B | 7.2751 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Feb-09-26 | Reiterated | H.C. Wainwright | Buy |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Downgrade | HSBC Securities | Hold → Reduce |
| Nov-06-25 | Upgrade | Stifel | Hold → Buy |
| Sep-25-25 | Initiated | Jefferies | Buy |
| Jul-21-25 | Resumed | Truist | Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-04-25 | Downgrade | Argus | Buy → Hold |
| Feb-11-25 | Initiated | Bernstein | Mkt Perform |
| Jan-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
Piper Sandler upgrades Biogen stock rating on acquisition strength By Investing.com - Investing.com India
Biogen stock upgraded at Piper Sandler (BIIB:NASDAQ) - Seeking Alpha
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Biogen, Birkenstock, Fastly, Ford, Lennox International, Netskope, SanDisk, Tesla, and More - 24/7 Wall St.
This Tesla Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For TuesdayBiogen (NASDAQ:BIIB), Croc - Benzinga
Apellis (APLS) board recommends $41 cash takeover by Biogen with up to $4 CVR - Stock Titan
Biogen (NASDAQ: APLS) bids $41 per share plus up to $4 CVR for Apellis - Stock Titan
Analyst recommendations: Biogen, Ford, Ge Vernova, Booking, Comcast… - marketscreener.com
Biogen Inc. stock (US09062X1037): Is Alzheimer's pipeline strength now the real test for upside? - AD HOC NEWS
Administrator Loeffler Applauds SBIR-STTR Reauthorization - GlobeNewswire Inc.
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Paragon Capital Management Acquires 6,686 Shares in Biogen - National Today
Will AbbVie's Neuroscience Franchise Aid Top-line Growth in Q1? - TradingView — Track All Markets
Biogen Inc. stock (US09062X1037): Does its neurology pipeline hold the key to renewed growth for U.S. investors? - AD HOC NEWS
Biogen to acquire Apellis for $5.6B to strengthen immunology portfolio - MSN
Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Biogen Inc (XSWX:BIIB)Valuation Measures & Financial Statistics - GuruFocus
Biogen Inc. stock (US09062X1037): Is the neurology focus strong enough to unlock new upside? - AD HOC NEWS
Today's Analyst Ratings Update for Biogen (BIIB): Key Changes | BIIB Stock News - GuruFocus
Today's Analyst Ratings Update for Biogen (BIIB): Key Changes | - GuruFocus
Biogen’s Alloy Antisense Deal Adds New Dimension To Genetic Medicine Bet - Sahm
Apellis Pharmaceuticals (APLS) hits 2-year high on 140% upside from Biogen merger - MSN
Biogen Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Boost for Cambridge as US company Alloy Therapeutics shows real Vigilance - Business Weekly
Is It Time To Reassess Biogen (BIIB) After Its 49% One Year Share Price Surge - simplywall.st
Biogen Inc. stock rises Wednesday, still underperforms market - MarketWatch
Biogen to use Alloy Therapeutics’ Anticlastic ASO platform - BioWorld News
Biogen (BIIB) Partners With Alloy Therapeutics on Antisense Drug Platform - MEXC Exchange
Biogen, Investors Reach Deal In Alzheimer's Drug Litigation - Law360
Biogen (NASDAQ: APLS) readies tender offer for Apellis under March 31, 2026 deal - Stock Titan
Why Biogen (BIIB) could beat earnings estimates again - MSN
Biogen’s ASO Strategy: How a $27B Giant is Investing $100M in a New Platform - Bitget
Why Biogen (BIIB) Could Beat Earnings Estimates Again - Yahoo Finance
Alloy Therapeutics and Biogen Announce Multi-Target Collaboration - National Today
Biogen taps Alloy platform to push antisense drug pipeline forward - MSN
Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy’s AntiClastic™ ASO Platform - BioSpace
What Is Driving Biogen’s Recent Drop and What Comes Next - Trefis
Biogen (BIIB) Stock Signs ASO Platform Deal With Alloy Therapeutics - CoinCentral
Biogen Taps Alloy Platform To Push Antisense Drug Pipeline Forward - Benzinga
RBC Capital Adjusts Biogen Price Target to $213 From $233, Maintains Outperform Rating - marketscreener.com
Alloy Therapeutics Partners with Biogen on Multi-Target Collaboration - National Today
Avoiding Lag: Real-Time Signals in (BIIB) Movement - Stock Traders Daily
Biogen’s Apellis Deal And High Dose SPINRAZA Shift Growth Outlook - simplywall.st
Alloy Therapeutics enters into multi-target collaboration and license agreement with Biogen for use of Alloy's Anticlastic™ ASO platform - marketscreener.com
Alloy Therapeutics Enters Into Multi-Target Collaboration And License Agreement With Biogen For Use Of Alloy’S Anticlastic™ Aso Platform - TradingView
Why Biogen (BIIB) May Surpass Earnings Projections Once More - Bitget
Why Biogen Stock Got Mashed on Monday - Yahoo Finance
Biogen (NASDAQ: APLS) files Form 3 on Apellis voting group status - Stock Titan
Biogen Discloses Tender Offer at Apellis with 14.2% Stake - TradingView — Track All Markets
[SCHEDULE 13D] Apellis Pharmaceuticals, Inc. Major Shareholder Acquisition (>5%) - Stock Titan
Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Move into Immunology - FinancialContent
Biogen : to Report First Quarter 2026 Financial Results April 29, 2026 - marketscreener.com
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
1.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):